This study examined the use of sitagliptin (Januvia) in patients with latent autoimmune diabetes.

This study evaluated the addition of linagliptin (Trajenta) to metformin (Glucophage) and lifestyle changes in patients with persistent prediabetes. The authors concluded that adding linagliptin after 12 months of metformin treatment and lifestyle changes improved glucose levels and pancreatic β-cell function in these patients. 

This study compared the effectiveness and tolerance of metformin (Glucophage) extended-release (MXR) and conventional metformin immediate-release (MIR) in adults with type 2 diabetes (T2D). The authors concluded that MIR had better glucose control while MXR but reduced gastrointestinal (GI) side effects.

This study examined whether treatments for prediabetes were effective at preventing type 2 diabetes in both men and women.

This review looked at whether medications similar to the GLP-1 hormone can improve liver health for people with type 2 diabetes (T2D) and fatty liver disease. It found that these medications can improve liver health and reduce fat in the liver.

This study evaluated the association between iron intake and the long-term risk of type 2 diabetes in women with gestational (pregnancy) diabetes. The authors concluded that a higher intake of total iron, dietary heme iron and supplemental iron are associated with a higher risk of T2D in women with a history of gestational diabetes.

This study examined the effectiveness of a combination of immunotherapies as a treatment for type 1 diabetes.

This study examined the safety and effectiveness of the addition of sitagliptin (Januvia) to insulin therapy in Asian type 2 diabetes patients. 

This study examined the effectiveness and safety of canagliflozin (Invokana), a glucose (sugar)-lowering therapy, in older adults (aged 55 to 80) with type 2 diabetes.